business resources

Top 20 AI Healthcare Platforms Transforming Medicine in 2025

Shikha Negi Content Contributor

22 Sept 2025, 3:30 pm GMT+1

AI is transforming healthcare, projected to save $150 billion annually and reach a $188 billion market by 2030. Platforms like Tempus AI lead with 90–95% diagnostic accuracy and precision medicine breakthroughs. With 80% of organisations adopting AI, how far can Tempus AI push the future of patient care?

Healthcare in 2025 is moving faster than ever before. Hospitals, clinics, and researchers are now turning to artificial intelligence not just as a tool, but as a true partner in saving lives. From spotting diseases earlier to designing treatments for each patient, AI is helping medicine become more precise, affordable, and accessible.

AI could save the global healthcare industry over $150 billion annually, thanks to gains in efficiency, early detection, and personalised care. Studies show that over 80% of healthcare organisations worldwide are either using or actively piloting AI solutions. AI can already detect certain cancers and cardiovascular conditions with an accuracy rate of 90–95%, often outperforming traditional methods.

The global AI in healthcare market is projected to reach $188 billion by 2030, growing at a CAGR of nearly 38%, with North America and Asia-Pacific leading adoption. AI is also reducing wait times. Virtual health assistants are expected to cut patient triage and consultation times by up to 60%, while AI-driven imaging analysis can deliver results 10x faster than manual reviews.

One of the names that often comes up in this space is Tempus AI. Known for its work in precision oncology and personalised medicine, Tempus AI is showing how data and technology can guide doctors to make better, faster decisions for patients. But it’s not the only platform shaping the future of healthcare. Let's explore all.

Why AI matters in Healthcare?

Artificial intelligence is no longer an experiment in healthcare; it is now a practical tool changing how doctors and patients experience medicine. 

Medical imaging and diagnostics- AI can now analyse X-rays, CT scans, and MRIs faster and more accurately than many radiologists. For instance, researchers at Stanford University have developed an AI that detects pneumonia from chest X-rays with an accuracy comparable to that of human specialists. Zebra Medical Vision and Aidoc are already helping hospitals flag critical conditions such as brain haemorrhages within minutes, saving precious time.

Early diagnosis and faster detection- One of the biggest advantages of AI is its ability to spot problems sooner than humans. Google’s DeepMind developed an AI system that can detect over 50 types of eye diseases from routine scans with the accuracy of leading specialists. In cancer care, Tempus AI leverages patient data and genomic sequencing to assist oncologists in selecting treatments with a higher likelihood of success.

Precision and personalised medicine- Medicine is no longer “one size fits all.” With AI platforms like Tempus AI, treatment plans are being tailored to each person’s biology. For instance, in breast cancer, AI can analyse tumour DNA to guide doctors toward therapies that specifically target mutations. This not only improves survival chances but also reduces unnecessary side effects.

Reducing the burden on healthcare staff- Healthcare professionals are under enormous pressure, especially after the pandemic. AI-driven tools are helping ease this strain. Babylon Health’s AI-powered chatbots, for example, handle millions of patient queries each month, allowing doctors to spend more time on complex cases. Similarly, hospitals are using AI to manage patient records and predict bed demand, making operations smoother.

Accelerating drug discovery- Traditionally, it can take up to 10–12 years to bring a new drug to market. AI platforms are cutting that timeline drastically. Companies like Insilico Medicine have already discovered potential drugs in under a year by using algorithms to model how molecules might interact with the body. This is life-changing for conditions where time is critical.

Making healthcare more affordable- AI is not just for high-tech hospitals. Start-ups are building low-cost diagnostic tools powered by machine learning that can be used in rural clinics or even via smartphones. For example, AI apps can now detect skin cancer from a simple photo, giving millions access to potentially life-saving information without expensive tests.

Top 20 AI Healthcare Platforms in 2025

Tempus AI

  • Website: https://www.tempus.com
  • Offering: AI-enabled precision medicine; molecular profiling; real-world data analytics; clinical trial matching; care pathway intelligence; generative assistant in EHRs.

Tempus AI is a US-based company that works by combining genomic sequencing, imaging, and real-world clinical records to help doctors tailor treatment to the individual. One of their newer programmes, called Fuses, uses their large data library (tens of millions of records, with many linked to imaging or transcriptomics) to build diagnostic, prognostic and predictive models. 

Their assistant tool, Tempus One, helps clinicians and researchers query unstructured data (e.g. texts, reports) using generative AI, making it easier to access relevant patient information. They also acquired Deep 6 AI, which helps match patients to clinical trials rapidly by analysing both structured and unstructured electronic health record data. One more special product is Tempus Next, a care pathway intelligence platform that spots gaps in treatment compared to guidelines, helping clinicians provide up-to-date therapy.  

Merative

Merative is a U.S.-based healthcare technology company that emerged from the divestiture of IBM Watson Health in 2022. Acquired by the private equity firm Francisco Partners, Merative operates as a standalone entity headquartered in Ann Arbour, Michigan. It specialises in providing data, analytics, and technology solutions to the health and government social services sectors. 

Merative's offerings include products like MarketScan, Micromedex, Merge, Truven Health Analytics, and Cúram, which support clinical decision-making, health data analytics, medical imaging, and social program management. Merative works with over 4,500 clients, including top U.S. hospitals, payers, Fortune 100 employers, government agencies, and pharmaceutical companies. Its portfolio includes trusted solutions like Micromedex, Merge, Truven, and Cúram, which support clinical decisions, patient care, and real-world insights. 

Google DeepMind Health

DeepMind, part of Google, is widely recognised for advancing AI research and applying it to medicine. The company has developed systems that detect more than 50 eye conditions with clinical accuracy and another tool that predicts acute kidney injury up to 48 hours in advance. Its strength lies in massive computing power and research expertise, enabling breakthroughs in healthcare that require huge datasets.

 In 2025, DeepMind continues to focus on early diagnosis, providing hospitals with tools that allow doctors to act before conditions become critical. Its work demonstrates how AI can prevent disease escalation and improve patient outcomes.

PathAI

  • Website: https://www.pathai.com/
  • Offering: AI-powered digital pathology, image management systems (AISight™), tumour microenvironment quantification (PathExplore), partnerships for diagnostic and translational research. 

PathAI builds AI tools for analysing pathology (tissue samples) at scale, to increase accuracy and speed diagnosis. Their system, AISight, lets pathologists and labs use algorithms that detect cancerous features in slides, quantify tissue regions and cellular structures, measure features like tumour-immune cell interactions (tumour microenvironment), and integrate with lab workflows and reporting. 

Their PathExplore panel, for example, extracts hundreds of quantitative features from biopsy slides, trained using millions of pathologist annotations. They also partner with biopharma companies to help with assay development and clinical trial biomarker work, aiding both diagnostics and treatment development.

Butterfly Network

  • Website:https://www.butterflynetwork.com/
  • Offerings: Ultrasound devices (e.g. Butterfly iQ, iQ+, etc.), plus AI software tools that help with live guidance, automated measurements, and tele-ultrasound capabilities.

Butterfly Network builds portable ultrasound devices that connect to smartphones/devices, with AI-powered tools to help with image acquisition, quality checks, and diagnostic assistance. Their aim is to enable more widespread access to ultrasound, especially in settings lacking expert radiologists or sonographers. 

In 2025, they joined a research project (CAD-LUS4TB) to test whether AI-assisted point-of-care ultrasound (POCUS) can help frontline health workers in Sub-Saharan Africa detect tuberculosis earlier. This trial involves around 3,000 adult patients and tests whether non-radiologists with AI support can identify signs of TB from ultrasound images. They also have AI applications like HeartFocus, a cardiac ultrasound app that guides any healthcare provider to get diagnostic-quality heart scans (with live guidance, auto capture, quality checks) even if not an expert sonographer.  

Zebra Medical Vision

Zebra Medical Vision uses deep learning to assist radiologists and healthcare systems by analysing medical scans (CT, MRI, X-ray, etc.) to flag abnormalities early. Its tools can detect lung disease, liver conditions, bone fractures, osteoporosis, cardiovascular risk, etc. 

What makes Zebra special is its “AI1” offering – a flat-price per scan model meant to make its algorithms affordable globally. It has regulatory approvals (e.g. FDA clearances) for several algorithms, and its imaging platforms are deployed in many hospitals around the world. For example, one of its recent approvals is for detecting vertebral compression fractures (VCF), helping screen for bone fragility, especially in older people.  

Insilico Medicine

  • Website: https://insilico.com/
  • Offering: AI-driven drug discovery, AI-designed gut-restricted inhibitor, Generative adversarial networks, GANs, and GANs-RL

Insilico Medicine uses AI throughout the drug discovery process, from identifying new disease targets, designing molecules, to advancing some candidates into trials. Examples: in early 2025, they reported positive Phase I trial results for ISM5411, an AI-designed gut-restricted inhibitor for inflammatory bowel disease. 

They also reached a preclinical milestone in a collaboration to develop treatments for metabolic dysfunction-associated steatohepatitis (MASH). Their internal pipeline uses tools like Chemistry42 for molecular design, and biological/medicine modules to predict safety and efficacy. Having raised strong investment (e.g. a US$110M Series E funding round in 2025), Insilico is one of the leaders in pushing generative AI into actual medicinal substances.

BenevolentAI

BenevolentAI is a UK- and UK-/Luxembourg-based company that builds tools to help scientists find new drug targets faster and support biopharma partners in developing treatments across many diseases. They use large knowledge graphs (which link genes, proteins, disease states, drug information, etc), and machine learning to propose novel targets, repurpose existing drug ideas, and validate them experimentally. In their collaboration with AstraZeneca, they recently discovered a new target for systemic lupus erythematosus (SLE), building on earlier target work in heart failure. 

In 2025, BenevolentAI has done a strategic overhaul: refocused on its core “tech-bio” mission, reorganised operations, and shifted toward making their AI tools more modular so partners can use them earlier in drug-development pipelines. They also delisted from Euronext Amsterdam and merged into a holding structure (Osaka Holdings) to streamline the corporate structure

Owkin

  • Website: https://www.owkin.com/
  • Offering: Federated AI platform for multimodal data, diagnostics, and collaborative drug discovery.

Owkin, a France-US biotech/AI company, works with hospitals, labs, and research centres to train AI on diverse patient data without centralising all data (to preserve privacy, via federated learning etc.). Their platform can handle different data types (images, molecular, pathology, clinical, etc.) to uncover biomarkers, predict outcomes, help match patients to treatments, and speed up drug development. Their “ATLANTIS” initiative (started in late 2024) maps 11 therapeutic areas (e.g. oncology, immunology, neurology) across 7 countries to unlock multimodal data for research.  

Another recent project is developing an IHC-dedicated foundation model (Immunohistochemistry images) in collaboration with NeoGenomics and France Tissue Bank, to improve biomarker quantification, tumour heterogeneity scoring, etc. This helps both diagnostics and drug development, especially for areas such as antibody-drug conjugates (ADCs). They also launched K Navigator in 2025, an AI co-pilot that helps researchers explore and validate hypotheses more rapidly, do literature reviews, visualise datasets, etc., to speed up discovery.

Ada Health

  • Website: https://ada.com/
  • Offering: AI-powered symptom assessment app + care navigation platform. It supports enterprise/providers as well.

Ada Health is based in Berlin and was founded in 2011. It provides tools that allow a user (patient) to enter symptoms and get guided assessments: likely causes, advice on what kind of care (self-care, doctor etc.), plus navigation features that help them find appropriate services. The platform is backed by a large medical knowledge base, many clinicians’ inputs, and supports many conditions including rare and mental health cases. 

Recently (2024-2025), Ada has grown quickly: over 50 million users, strong year-on-year revenue growth, profitability in some segments, expansion of the leadership team for product and business development, and improved product accuracy vs comparator assessment tools. 

Exscientia

  • Website: https://www.exscientia.ai/
  • Offering: AI-driven drug discovery; partnerships/collaborations with large pharma; receiving milestone payments for achievements in compound development. 

Exscientia is a UK-based company innovating in the field of AI-designed drug discovery. Their platform uses machine learning models to generate, evaluate and optimise molecules for disease treatment, aiming to speed up the discovery process and reduce time/costs typically required.

Several of their programmes in collaboration with Sanofi have passed early milestone gates, earning Exscientia upfront payments and setting up potential future royalties and bigger milestone rewards. Their tools seek both “quality and speed” in finding lead compounds and candidates for development. They also won the Prix Galien USA Award in 2022 for their digital health solution platform. 

 AliveCor

  • Website: https://www.alivecor.com/
  • Offering: Personal ECG devices (home use), real-time AI-powered ECG analysis, clinician portals for remote patient monitoring, enterprise programmes for heart disease management.  

AliveCor specialises in heart health monitoring using portable ECG (electrocardiogram) devices that users can use at home. Their devices are validated and cleared by regulators; they detect common arrhythmias (such as atrial fibrillation) and provide ECG data that patients can share with medical professionals. For healthcare providers, there is KardiaPro – a web portal for managing remote ECG, BP, weight data etc., supporting monitoring beyond in-clinic visits. 

They also offer “KardiaComplete,” a programme combining devices, coaching, and specialist access, aimed at people with existing cardiovascular disease or risk. In many countries, AliveCor’s tools let users integrate ECG data into medical records; in India, for example, their six-lead device is available and positioned as a way for early detection and prevention of heart problems. 

Qure.ai

  • Website: https://www.qure.ai/
  • Offering: AI solutions- chest X-rays, TB care, lung cancer management, stroke, and heart failure.

Qure.ai is a health tech company that uses Artificial Intelligence (AI) to make healthcare more affordable and accessible for people around the world. By using deep learning, Qure.ai provides AI solutions that help medical professionals interpret radiology exams like X-rays, CT scans, and ultrasounds. This helps doctors diagnose conditions faster and start treatment more quickly. 

Qure.ai’s solutions support the identification and management of diseases like Tuberculosis (TB), lung cancer, stroke, and more. Their mission is to improve patient care by making healthcare more efficient and improving treatment outcomes for patients globally.

NVIDIA Clara

NVIDIA Clara is a suite of tools and frameworks meant for researchers, device makers and healthcare providers to build, deploy and operate medical AI. It includes Clara Holoscan, which lets developers build real-time, high-performance AI for medical devices and sensors; Clara Guardian, which supports sensors, video, speech and edge-AI in hospital environments for safety, patient monitoring, PPE compliance etc. 

MONAI, a set of standard tools for imaging AI; and hardware reference stacks for deploying AI close to where data is created (at the “edge”). It helps ensure that AI applications are both performant and compliant, with support for regulatory and operational needs. 

Medtronic

Medtronic integrates AI into medical devices to help detect conditions earlier and assist clinicians in real time. It uses AI in various applications, such as the GI Genius™ AI-assisted colonoscopy tool for early detection of colorectal cancer, the MiniMed™ 780G insulin pump for automated blood sugar regulation in diabetes patients, and the AccuRhythm™ AI for more accurate heart rhythm detection. Medtronic also integrates AI into its neurosurgical tools and cardiac monitors, ensuring precision in surgery and diagnostics

For over 60 years, the company has been at the forefront of innovation, developing groundbreaking solutions to treat over 70 complex conditions.  Apart from diagnostic imaging, Medtronic uses sensors and pattern recognition in implantables and monitoring devices to track heart rhythms, breathing, etc., feeding, teaching and predictive analytics to provide more personalised care. They emphasise real-time responses, safety, regulatory clearances, and deploying AI in settings where accuracy and speed are critical.

Caption Health

  • Website: https://www.gehealthcare.com/
  • Offering: AI-driven drug discovery, AI-designed gut-restricted inhibitor, Generative adversarial networks, GANs, and GANs-RL

GE HealthCare to acquire Caption Health, expanding ultrasound to support new users through FDA-cleared, AI-powered image guidance. Their software, Caption AI, gives real-time guidance while scanning: it shows how to move the probe, gives feedback on image quality, and once good enough, records diagnostic images automatically. 

It also has interpretation (for example, calculating ejection fraction for heart function). Because of this, more care settings (clinics, even patients’ homes) can have useful ultrasound without needing expert sonographers everywhere. GE HealthCare acquired Caption Health in 2023, which gives it a stronger reach and resources. It has also received grants (e.g. from Bill & Melinda Gates Foundation) to adapt its technology for low- and middle-income countries and to extend it beyond cardiac ultrasound (e.g. lung ultrasound).

Philips Healthcare

Philips is using AI to make imaging, diagnosis, workflow and patient monitoring smarter and faster. Their Elevate platform upgrade adds AI automation to ultrasound machines, improving image quality, automating pre-sets, adjusting settings automatically, and facilitating remote monitoring/assistance. 

Their IntelliSpace AI Workflow Suite helps hospitals run multiple AI applications in imaging & radiology workflows, linking data from devices, imaging systems, RIS/PACS/HIS, etc. HealthSuite Insights provides tools, cloud infrastructure, marketplaces, and analytics capabilities to build, deploy, and scale AI solutions securely and compliantly. Philips aims to reduce the burden on clinicians, improve diagnostic confidence, speed up imaging workflows, and widen access to quality diagnostic tools. 

OpenEvidence

OpenEvidence is focused on giving doctors fast, trustworthy answers by drawing on the scientific literature. Its main tool, OpenEvidence Search, lets verified physicians search through tens of millions of peer-reviewed publications with fast, well-cited results tuned for clinical decision support. 

When facing a complex case, DeepConsult (an AI agent) can synthesise many studies simultaneously to produce a research brief, helping clinicians understand trade-offs or evidence for different treatment paths. Used in thousands of hospitals and medical centres in the U.S., the platform helps reduce the time spent reading, keep up to date, and make more evidence-based choices in patient care.

Heidi Health

Heidi Health, based in Melbourne, is the creator of one of the world’s most widely used AI scribes, trusted daily by tens of thousands of clinicians across more than 50 countries. Unlike simple transcription tools, Heidi goes further by personalising notes through custom templates, generating any medical document from a prompt, and supporting shared sessions that allow multiple specialists to collaborate on the same case. 

This makes it useful for solo GPs to large hospitals, across fields from primary care to neurology and obstetrics. Its software is HIPAA and NHS compliant, with SOC2 and ISO 27001 certification, ensuring patient data security. Heidi is free to start, making it highly accessible.

Prognos Health

  • Website: https://prognoshealth.com/
  • Offering: harmonised clinical and genomic laboratory data, combined with claims & analytics tools

Prognos Health specialises in assembling de-identified lab and genomic test data from numerous sources, integrating it with health records and claims to produce ready-to-use datasets. With over 200+ million patients represented (and more than 325 million lab records), their platform supports uses like oncology, rare disease insights, commercial analytics, precision-marketing, and understanding patient treatment journeys.

They reduce the time needed to get usable real-world data (RWD) by delivering data ready for analysis in as little as 30 days, rather than the typical many-month delays. Their models and data help pharma, biotech, and healthcare providers make better decisions faster. 

Share this

Shikha Negi

Content Contributor

Shikha Negi is a Content Writer at ztudium with expertise in writing and proofreading content. Having created more than 500 articles encompassing a diverse range of educational topics, from breaking news to in-depth analysis and long-form content, Shikha has a deep understanding of emerging trends in business, technology (including AI, blockchain, and the metaverse), and societal shifts, As the author at Sarvgyan News, Shikha has demonstrated expertise in crafting engaging and informative content tailored for various audiences, including students, educators, and professionals.

previous

King Billy Top Casino Games

next

Getting Paperwork Done Without Stress

More Articles